Pliant Therapeutics, Inc. financial data

Symbol
PLRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
331 Oyster Point Boulevard, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.69K % -6.84%
Debt-to-equity 13.9 % +56.4%
Return On Equity -41.1 % -24%
Return On Assets -36 % -18.6%
Operating Margin -78.4K % -5328%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.8M shares +1.62%
Common Stock, Shares, Outstanding 60.4M shares +2.03%
Entity Public Float 1.01B USD +258%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.4M shares +2.05%
Weighted Average Number of Shares Outstanding, Diluted 60.4M shares +2.05%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 148M USD +32.4%
General and Administrative Expense 59.5M USD +14.8%
Operating Income (Loss) -208M USD -30.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -185M USD -28.4%
Earnings Per Share, Basic -3.08 USD/shares -13.7%
Earnings Per Share, Diluted -3.08 USD/shares -13.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.4M USD +46.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 448M USD -20.9%
Property, Plant and Equipment, Net 5.4M USD +24.5%
Operating Lease, Right-of-Use Asset 28.9M USD +590%
Other Assets, Noncurrent 437K USD -35%
Assets 484M USD -15.9%
Accounts Payable, Current 3.25M USD +40.6%
Employee-related Liabilities, Current 6.61M USD +15%
Accrued Liabilities, Current 8.2M USD +21.2%
Liabilities, Current 30.9M USD +4.76%
Operating Lease, Liability, Noncurrent 30.1M USD +1197%
Liabilities 91.1M USD +118%
Accumulated Other Comprehensive Income (Loss), Net of Tax -617K USD +72.5%
Retained Earnings (Accumulated Deficit) -603M USD -44.4%
Stockholders' Equity Attributable to Parent 393M USD -26.3%
Liabilities and Equity 484M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.3M USD +0.02%
Net Cash Provided by (Used in) Financing Activities 21.8M USD -92%
Net Cash Provided by (Used in) Investing Activities 59.5M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.4M shares +2.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 51.1M USD -25.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 81.9M USD +49%
Interest Paid, Excluding Capitalized Interest, Operating Activities 501K USD +77.7%
Deferred Tax Assets, Valuation Allowance 154M USD +45.7%
Deferred Tax Assets, Gross 155M USD +43.4%
Operating Lease, Liability 6.45M USD
Depreciation 2.1M USD +15.5%
Payments to Acquire Property, Plant, and Equipment 1.49M USD +815%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -184M USD -26.4%
Lessee, Operating Lease, Liability, to be Paid 43.4M USD
Property, Plant and Equipment, Gross 15.2M USD +25.7%
Operating Lease, Liability, Current 98K USD -95.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.41M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.55M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -29.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13.3M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.9M USD
Deferred Tax Assets, Operating Loss Carryforwards 78.5M USD +19.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.97M USD +53.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.47M USD
Operating Lease, Payments 800K USD +33.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 39.8M USD -1.99%
Interest Expense 1.4M USD +27.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares